Construction of recombinant vaccinia virus co-expressing mutant E6 plus E7 proteins and detection of its immunogenicity and antitumor response.
- Author:
Huijun ZHI
1
;
Liqun HAN
;
Jiao REN
;
Houwen TIAN
;
Weifeng LUO
;
Yu LIANG
;
Li RUAN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Female; Genes, Viral; genetics; Genetic Vectors; genetics; immunology; Mice; Mice, Inbred C57BL; Mutation; Neoplasms, Experimental; prevention & control; Oncogene Proteins, Viral; genetics; Papillomaviridae; genetics; Papillomavirus E7 Proteins; Recombination, Genetic; Repressor Proteins; Transfection; Vaccinia virus; genetics; immunology
- From: Chinese Journal of Experimental and Clinical Virology 2002;16(4):341-344
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo generate a candidate HPV16 vaccine for experimental and therapeutical use for cervical cancer.
METHODSThe mutants of HPV16 early E6 and E7 genes were inserted into a vaccinia virus expression vector. A strain of recombinant vaccinia virus was constructed through homologous recombination.
RESULTSShowed that the mutant E6 and E7 genes were located at TK gene region of vaccinia virus Tiantan strain in a head to head orientation under the control of early/late promoters, H6 and 7.5K respectively. Studies in mice indicated that VmE6E7 could elicit specific antibodies against E6 and E7, and retarded or prevented tumor development in a proportion of C57 BL/6 mice challenged by syngeneic HPV16E6 and E7 transformed tumor cells.
CONCLUSIONSThe success in constructing VmE6E7 provides a basis for the further development of HPV16 therapeutic vaccine.
